We have previously demonstrated that the CCR9/CCL25 signaling pathway plays an important role in drug resistance in human acute T-lymphocytic leukemia (T-ALL) by inducing activation of ERM protein with polarized distribution in T-ALL cell line MOLT4. However, the mechanism of action of the activated ERM protein in the drug resistance of MOLT4 cells induced by CCL25 remains uncharacterized. Here we investigated the mechanism of CCR9/CCL25-initiated drug resistance in CCR9-high-expressing T-ALL cells. Our results showed that 1) the function of P-gp was increased after treatment with CCL25; 2) P-gp colocalized and co-immunoprecipitated with p-ERM and F-actin in CCL25 treated cells; and 3) ERM-shRNA conferred drug sensitivity coincident with release of ERM interactions with P-gp and F-actin after treatment with CCL25. These data suggest it is pivotal that P-gp associate with the F-actin cytoskeleton through p-ERM in CCR9/CCL25 induced multidrug resistance of T-ALL cells. Strategies aimed at inhibiting P-gp-F-actin cytoskeleton association may be helpful in increasing the efficiency of therapies in T-ALL.
References
[1]
Pui CH, Behm FG, Crist WM (1993) Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82: 343–362.
[2]
Willemse MJ, Seriu T, Hettinger K, d'Aniello E, Hop WC, et al. (2002) Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 99 (12) 4386–4393.
[3]
Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580: 998–1009.
[4]
Sharon FJ (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9 (1) 105–127.
[5]
Meschini S, Calcabrini A, Monti E, Del Bufalo D, Stringaro A, et al. (2000) Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. Int J Cancer 87 (5) 615–628.
[6]
Arora A, Seth K, Shukla Y (2004) Reversal of P-glycoprotein-mediated multidrug resistance by dially1 sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis 25 (6) 941–949.
[7]
Zhou B, Leng J, Hu M, Zhang L, Wang Z, et al. (2010) Ezrin is a key molecule in the metastasis of MOLT4 cells induced by CCL25/CCR9. Leukemia research 34 (6) 769–776.
[8]
Bretscher A (1999) Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol 11 (1) 109–116.
[9]
Saarikangas J, Zhao H, Lappalainen P (2010) Regulation of the actin cytoskeleton- plasma membrane interplay by phosphoinositides. Physiol Rev 90 (1) 259–289.
[10]
Luna EJ, Hitt AL (1992) Cytoskeleton-plasma membrane interactions. Science 258: 955–963.
[11]
Hébert M, Potin S, Sebbagh M, Bertoglio J, Bréard J, et al. (2008) Rho-ROCK-dependent ezrin-radixin-moesin phosphorylation regulates Fas-mediated apoptosis in Jurkat cells. J Immunol 181 (9) 5963–5973.
[12]
Luciani F, Molinari A, Lozupone F, Calcabrini A, Lugini L, et al. (2002) P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood 99 (2) 641–648.
[13]
Brambilla D, Zamboni S, Federici C, Lugini L, Lozupone F, et al. (2012) P-glycoprotein binds to ezrin at amino acid residues 149–242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma. Int J Cancer 130 (12) 2824–2834.
[14]
Rodriguez-Boulan E, Nelson WJ (1989) Morphogenesis of the polarized epithelial cell phenotype. Science 245 (4919) 718–725.
[15]
Padányi R, Xiong Y, Antalffy G, Lór K, Pászty K, et al. (2010) Apical scaffolding protein NHERF2 modulates the localization of alternatively spliced plasma membrane Ca2+ pump 2B variants in polarized epithelial cells. J Biol Chem 285 (41) 31704–31712.
[16]
Tong X, Zhang L, Zhang L, Hu M, Leng J, et al. (2009) The Mechanism of Chemokine Receptor 9 Internalization Triggered by Interleukin 2 and Interleukin 4. Cellular & Molecular Immunology 6 (3) 181–189.
[17]
Qiuping Z, Jei X, Youxin J, Wei J, Chun L, et al. (2004) CC Chemokine Ligand 25 Enhances Resistance to Apoptosis in CD4+ T Cell from Patients with T-cell Lineage Acute and Chronic Lymphocytic Leukemia by means of Livin Activation. Cancer Research 64: 7579–7587.
[18]
Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, et al. (2002) Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Cancer Chemother Pharmacol 49 (5) 391–397.
[19]
Hayashi K, Yonemura S, Matsui T, Tsukita S (1999) Immunofluorescence detection of ezrin/radixin/moesin (ERM) proteins with their carboxyl-terminal threonine phosphorylated in cultured cells and tissues. J Cell Sci 112 (Pt 8) 1149–1158.
[20]
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41 (5) 1967–1972.
[21]
Galski H, sivan H, Lazarovici P, Nagler A (2006) In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: Implications on hematologic malignancies. Leukemia Research 30 (9) 1151–1158.
[22]
Asakura K, Uchida H, Miyachi H, Kobayashi H, Miyakawa Y, et al. (2004) TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-gene expression. Molecular Cancer Research 2 (6) 339–347.
[23]
Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (1) 48–58.
[24]
Raaijmakers MH (2007) ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia 21: 2094–2102.
[25]
Wisser RJ, Kolkman JM, Patzoldt ME, Holland JB, Yu J, et al. (2011) Multivariate analysis of maize disease resistances suggests a pleiotropic genetic basis and implicates a GST gene. Proc Natl Acad Sci 108 (18) 7339–7344.
[26]
Rudd LP, Kabler SL, Morrow CS, Townsend AJ (2011) Enhanced glutathione depletion, protein adduct formation, and cytotoxicity following exposure to 4-hydroxy-2-nonenal (HNE) in cells expressing human multidrug resistance protein-1 (MRP1) together with human glutathione S-transferase-M1 (GSTM1). Chemico-Biological Interactions 194 (2–3) 113–119.
[27]
Cohen JD, Tham KY, Mastrandrea NJ, Gallegos AC, Monks TJ, et al. (2011) cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. Toxicol Sci 122 (2) 361–371.
[28]
Ding K, Su Y, Pang L, Lu Q, Wang Z, et al. (2009) Inhibition of apoptosis by downregulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/Abl+ leukemic cells. Carcinogenesis 30 (1) 35–42.
[29]
Kater L, Claffey J, Hogan M, Jesse P, Kater B, et al. (2012) The role of the intrinsic FAS pathway in Titanocene Y apoptosis: The mechanism of overcomingmultiple drug resistance in malignant leukemia cells. Toxicol In Vitro 26 (1) 119–124.
[30]
Stege A, Priebsch A, Nieth C, Lage H (2004) Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther 11 (11) 699–706.
[31]
Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, et al. (2007) CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 109 (10) 4168–4170.
[32]
Fu D, Roufogalis BD (2007) Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation. Am J Physiol Cell Physiol 292 (4) C1543–1552.
[33]
Goler-Baron V, Assaraf YG (2011) Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance. PLoS One 6 (1) e16007.
[34]
Lallemand D, Saint-Amaux AL, Giovannini M (2009) Tumor-suppression functions of merlin are independent of its role as an organizer of the actincytoskeleton in Schwann cells. J Cell Sci 122 (Pt 22) 4141–4149.
[35]
Brown KL, Birkenhead D, Lai JC, Li L, Li R, et al. (2005) Regulation of hyaluronan binding by F-actin and colocalization of CD44 and phosphorylated ezrin/radixin/moesin (ERM) proteins in myeloid cells. Exp Cell Res 303 (2) 400–414.
[36]
Molinari A, Calcabrini A, Meschini S, Stringaro A, Crateri P, et al. (2002) Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells. Curr Protein Pept Sci 3 (6) 653–670.
[37]
Villar VH, V？gler O, Martínez-Serra J, Ramos R, Calabuig-Fari？as S, et al. (2012) Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. Plos One 7 (5) e37735.
